Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is inter alia to enhance the company’s financial position ahead of negotiating a deal pertaining to its lead product HyNap-Dasa and to continue to expand the company’s product portfolio.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson and Linnea Petersson.

Related

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024

Vinge advises Sobro in connection with investment in Clinton Marine Survey

Clinton Marine Survey has chosen to broaden its ownership with Sobro as a new partner and majority shareholder. All existing owners remain as significant shareholders. Clinton Marine Survey offers high quality hydrographic and geological surveys for navigation, dredging operations, mapping, marine construction and more.
April 09, 2024

Vinge has advised Helix Kapital in connection with the fund formation of Helix Kapital Fund III

Vinge has advised Helix Kapital in the establishment of Helix Kapital’s third fund, Helix Kapital Fund III. The fund closed successfully with commitments of approximately SEK 1.5 billion from an international investor base consisting of a number of leading financial institutions. The investor interest in the fund raising was very strong, and the fund was significantly oversubscribed.
April 05, 2024